Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease.

Literature DB >> 33919434

Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease.

Abstract

Unmet needs in the treatment of psoriasis call for novel therapeutic strategies. Pustular psoriasis and psoriatic arthritis often represent a therapeutic challenge. Focus on IL-36 cytokines offers an interesting approach, as the IL-36 axis has been appointed a critical driver of the autoinflammatory responses involved in pustular psoriasis. Two IL-36R blocking antibodies, imsidolimab and spesolimab, are currently undergoing phase II and III clinical trials, with promising results.

Entities: Chemical Disease Gene Species

Keywords: IL-36; IL-36R; imsidolimab; pathogenesis; psoriasis; psoriatic arthritis; pustular psoriasis; spesolimab

Year: 2021 PMID： 33919434 DOI： 10.3390/ijms22094344

Source DB: PubMed Journal: Int J Mol Sci ISSN： 1422-0067 Impact factor: 5.923

54 in total

1. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis.

Authors: Alexandros Onoufriadis; Michael A Simpson; Andrew E Pink; Paola Di Meglio; Catherine H Smith; Venu Pullabhatla; Jo Knight; Sarah L Spain; Frank O Nestle; A David Burden; Francesca Capon; Richard C Trembath; Jonathan N Barker
Journal: Am J Hum Genet Date: 2011-08-11 Impact factor: 11.025

Review 2. Psoriatic arthritis.

Authors: J M Moll; V Wright
Journal: Semin Arthritis Rheum Date: 1973 Impact factor: 5.532

3. Enhanced IL-36R signaling promotes barrier impairment and inflammation in skin and intestine.

Authors: Zaruhi Hovhannisyan; Nengyin Liu; Sara Khalil-Aguero; Casandra Panea; Jeffrey VanValkenburgh; Ruoyu Zhang; Wei Keat Lim; Yu Bai; Wen Fury; Tammy Huang; Elena Garnova; Jeanette Fairhurst; Jee Kim; Smita Aryal; Dharani Ajithdoss; Adelekan Oyejide; Maria Del Pilar Molina-Portela; Hock E; William Poueymirou; Nicole Stokes Oristian; Susannah Brydges; Xia Liu; William Olson; George Yancopoulos; Andrew J Murphy; Matthew A Sleeman; Sokol Haxhinasto
Journal: Sci Immunol Date: 2020-12-18

Review 4. European consensus statement on phenotypes of pustular psoriasis.

Authors: A A Navarini; A D Burden; F Capon; U Mrowietz; L Puig; S Köks; K Kingo; C Smith; J N Barker
Journal: J Eur Acad Dermatol Venereol Date: 2017-08-29 Impact factor: 6.166

5. Clinical and radiological changes during psoriatic arthritis disease progression.

Authors: Mustafa Khan; Catherine Schentag; Dafna D Gladman
Journal: J Rheumatol Date: 2003-05 Impact factor: 4.666

6. Alarmin function of cathelicidin antimicrobial peptide LL37 through IL-36γ induction in human epidermal keratinocytes.

Authors: Na Li; Kenshi Yamasaki; Rumiko Saito; Sawako Fukushi-Takahashi; Ryoko Shimada-Omori; Masayuki Asano; Setsuya Aiba
Journal: J Immunol Date: 2014-10-10 Impact factor: 5.422

Review 7. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review.

Authors: April W Armstrong; Charlotte Read
Journal: JAMA Date: 2020-05-19 Impact factor: 56.272

8. Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes.

Authors: Niovi Setta-Kaffetzi; Alexander A Navarini; Varsha M Patel; Venu Pullabhatla; Andrew E Pink; Siew-Eng Choon; Michael A Allen; A David Burden; Christopher E M Griffiths; Marieke M B Seyger; Brian Kirby; Richard C Trembath; Michael A Simpson; Catherine H Smith; Francesca Capon; Jonathan N Barker
Journal: J Invest Dermatol Date: 2013-01-10 Impact factor: 8.551

9. Neutrophil Elastase-mediated proteolysis activates the anti-inflammatory cytokine IL-36 Receptor antagonist.

Authors: Tom Macleod; Rosella Doble; Dennis McGonagle; Christopher W Wasson; Adewonuola Alase; Martin Stacey; Miriam Wittmann
Journal: Sci Rep Date: 2016-04-22 Impact factor: 4.379

10. IL-36 Promotes Systemic IFN-I Responses in Severe Forms of Psoriasis.

Authors: Marika Catapano; Marta Vergnano; Marco Romano; Satveer K Mahil; Siew-Eng Choon; A David Burden; Helen S Young; Ian M Carr; Helen J Lachmann; Giovanna Lombardi; Catherine H Smith; Francesca D Ciccarelli; Jonathan N Barker; Francesca Capon
Journal: J Invest Dermatol Date: 2019-09-17 Impact factor: 8.551

13 in total

Review 1. Transcriptional Basis of Psoriasis from Large Scale Gene Expression Studies: The Importance of Moving towards a Precision Medicine Approach.

Authors: Vidya S Krishnan; Sulev Kõks
Journal: Int J Mol Sci Date: 2022-05-30 Impact factor: 6.208

Review 2. Generalized Pustular Psoriasis in Pregnancy: Current and Future Treatments.

Authors: Mariko Seishima; Kento Fujii; Yoko Mizutani
Journal: Am J Clin Dermatol Date: 2022-06-15 Impact factor: 6.233

Review 3. Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases.

Authors: Hideyuki Ujiie; David Rosmarin; Michael P Schön; Sonja Ständer; Katharina Boch; Martin Metz; Marcus Maurer; Diamant Thaci; Enno Schmidt; Connor Cole; Kyle T Amber; Dario Didona; Michael Hertl; Andreas Recke; Hanna Graßhoff; Alexander Hackel; Anja Schumann; Gabriela Riemekasten; Katja Bieber; Gant Sprow; Joshua Dan; Detlef Zillikens; Tanya Sezin; Angela M Christiano; Kerstin Wolk; Robert Sabat; Khalaf Kridin; Victoria P Werth; Ralf J Ludwig
Journal: Front Med (Lausanne) Date: 2022-06-09

Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease.

1. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis.

Review 2. Psoriatic arthritis.

3. Enhanced IL-36R signaling promotes barrier impairment and inflammation in skin and intestine.

Review 4. European consensus statement on phenotypes of pustular psoriasis.

5. Clinical and radiological changes during psoriatic arthritis disease progression.

6. Alarmin function of cathelicidin antimicrobial peptide LL37 through IL-36γ induction in human epidermal keratinocytes.

Review 7. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review.

8. Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes.

9. Neutrophil Elastase-mediated proteolysis activates the anti-inflammatory cytokine IL-36 Receptor antagonist.

10. IL-36 Promotes Systemic IFN-I Responses in Severe Forms of Psoriasis.

Review 1. Transcriptional Basis of Psoriasis from Large Scale Gene Expression Studies: The Importance of Moving towards a Precision Medicine Approach.

Review 2. Generalized Pustular Psoriasis in Pregnancy: Current and Future Treatments.

Review 3. Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases.

4. IL-36γ in enthesitis-related juvenile idiopathic arthritis and its association with disease activity.

Review 5. Advances in the pathogenesis of psoriasis: from keratinocyte perspective.

Review 6. Autoinflammatory Diseases and Cytokine Storms-Imbalances of Innate and Adaptative Immunity.

Review 7. Pathophysiology of Generalized Pustular Psoriasis.

Review 8. Current Status, Issues and Future Prospects of Personalized Medicine for Each Disease.

Review 9. Pustular Psoriasis: From Pathophysiology to Treatment.

Review 10. IL-36 cytokines in inflammatory and malignant diseases: not the new kid on the block anymore.